PL1692516T3 - Sposób terapii - Google Patents

Sposób terapii

Info

Publication number
PL1692516T3
PL1692516T3 PL04761461T PL04761461T PL1692516T3 PL 1692516 T3 PL1692516 T3 PL 1692516T3 PL 04761461 T PL04761461 T PL 04761461T PL 04761461 T PL04761461 T PL 04761461T PL 1692516 T3 PL1692516 T3 PL 1692516T3
Authority
PL
Poland
Prior art keywords
present
diseases
therapy
production
relates
Prior art date
Application number
PL04761461T
Other languages
English (en)
Inventor
Martin Leonard Ashdown
Original Assignee
Immunaid Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003905858A external-priority patent/AU2003905858A0/en
Application filed by Immunaid Pty Ltd filed Critical Immunaid Pty Ltd
Publication of PL1692516T3 publication Critical patent/PL1692516T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL04761461T 2003-10-24 2004-10-22 Sposób terapii PL1692516T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003905858A AU2003905858A0 (en) 2003-10-24 Method of therapy
EP04761461A EP1692516B1 (en) 2003-10-24 2004-10-22 Method of therapy
PCT/AU2004/001456 WO2005040816A1 (en) 2003-10-24 2004-10-22 Method of therapy

Publications (1)

Publication Number Publication Date
PL1692516T3 true PL1692516T3 (pl) 2011-05-31

Family

ID=34468632

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04761461T PL1692516T3 (pl) 2003-10-24 2004-10-22 Sposób terapii

Country Status (16)

Country Link
US (5) US20070202119A1 (pl)
EP (2) EP2270511A3 (pl)
JP (2) JP4931593B2 (pl)
CN (1) CN1898569A (pl)
AT (1) ATE490470T1 (pl)
BR (1) BRPI0415533A (pl)
CA (1) CA2543490A1 (pl)
DE (1) DE602004030369D1 (pl)
DK (1) DK1692516T3 (pl)
ES (1) ES2357430T3 (pl)
IL (1) IL175141A0 (pl)
NZ (1) NZ546873A (pl)
PL (1) PL1692516T3 (pl)
PT (1) PT1692516E (pl)
RU (1) RU2006117793A (pl)
WO (1) WO2005040816A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPS065002A0 (en) * 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
PL1692516T3 (pl) * 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
AU2005282218B2 (en) * 2004-09-08 2012-04-12 Biotempus Pty Ltd Therapeutic strategy for treating autoimmune and degenerative diseases
DK1805510T3 (da) * 2004-09-08 2012-04-30 Immunaid Pty Ltd Terapeutisk strategi til behandling af autoimmune og degenerative sygdomme
US8775207B2 (en) * 2005-02-02 2014-07-08 Siemens Medical Solutions Usa, Inc. Integrated treatment planning and scheduling system
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP3444358A1 (en) * 2009-02-20 2019-02-20 Onconome, Inc. Methods for diagnosis and prognosis of colorectal cancer
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
SG168431A1 (en) * 2009-07-23 2011-02-28 Univ Singapore Cancer biomarker and the use thereof
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
WO2011075225A1 (en) * 2009-12-17 2011-06-23 Mayo Foundation For Medical Education And Research Determination of favorable time(s) for chemotherapy delivery
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013277344B2 (en) * 2012-06-18 2016-09-08 Mayo Foundation For Medical Education And Research Determination of efficient time(s) for chemotherapy delivery
KR101534462B1 (ko) * 2012-07-31 2015-07-06 한림대학교 산학협력단 사이클린 ａ2 저해제를 포함하는 ｃ형간염 예방 및 치료용 조성물
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CN103941021B (zh) * 2014-05-09 2017-02-01 深圳市国赛生物技术有限公司 一种检测白细胞介素‑6的试剂盒以及非诊断目的检测白细胞介素‑6的方法
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
WO2016015095A1 (en) * 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
CN117789914A (zh) * 2014-12-05 2024-03-29 生命循环科技私人有限公司 改善生理反应的方法和系统
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP2016148623A (ja) * 2015-02-13 2016-08-18 京都府公立大学法人 大腸がんの検出方法
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
DE3812605A1 (de) 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
US20020094542A1 (en) * 1988-04-15 2002-07-18 Peter Leskovar Drugs and methods for treating cancer
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
ATE135113T1 (de) 1988-12-20 1996-03-15 Clarity Technologies Inc Synthetische hiv ähnliche peptide, deren zusammensetzungen und verwendungen
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
DE4120296A1 (de) 1991-06-28 1992-03-19 Regina Tilgner Rein pflanzliches kombinationspraeparat - gegen aids
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US5358852A (en) * 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6110898A (en) 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
US20040203024A1 (en) 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6107020A (en) * 1996-09-20 2000-08-22 Roger Williams Hospital Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof
US7030152B1 (en) * 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
JPH11271304A (ja) * 1998-03-24 1999-10-08 Jcr Pharmaceuticals Co Ltd Ｈｉｖ感染の診断方法
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
AU779494B2 (en) * 1999-07-28 2005-01-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotherapy in HIV infected persons using vaccines after multi-drug treatment
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPS065002A0 (en) * 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
AUPQ948800A0 (en) * 2000-08-18 2000-09-07 Immunaid Pty Ltd A vaccine strategy
WO2002045735A2 (en) 2000-12-08 2002-06-13 University Technologies International, Inc. Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US20060134713A1 (en) * 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
MXPA05004722A (es) 2002-11-01 2005-08-03 Univ Pennsylvania Composiciones y metodos para la inhibicion del factor inducible por hipoxia 1 alfa con acido ribonucleico corto de interferencia.
EP1567539B1 (en) 2002-11-04 2009-09-23 University of Massachusetts Allele-specific rna interference
EP2347767A3 (en) 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2005034995A1 (en) 2003-09-10 2005-04-21 Chiron Corporation Prion chimeras and uses thereof
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
JP2007538000A (ja) 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する
EP1711208A2 (en) 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
DK1805510T3 (da) * 2004-09-08 2012-04-30 Immunaid Pty Ltd Terapeutisk strategi til behandling af autoimmune og degenerative sygdomme
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
US8131325B2 (en) * 2009-02-27 2012-03-06 Research In Motion Limited Method, apparatus and system for battery resource management via traffic steering
HUE026456T2 (en) * 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases

Also Published As

Publication number Publication date
US20140051100A1 (en) 2014-02-20
US20140065644A1 (en) 2014-03-06
US20120156225A1 (en) 2012-06-21
EP1692516A1 (en) 2006-08-23
PT1692516E (pt) 2011-03-07
RU2006117793A (ru) 2007-12-10
EP1692516B1 (en) 2010-12-01
JP2007509078A (ja) 2007-04-12
US8524651B2 (en) 2013-09-03
US20150377882A1 (en) 2015-12-31
CN1898569A (zh) 2007-01-17
ES2357430T3 (es) 2011-04-26
EP1692516A4 (en) 2008-09-24
CA2543490A1 (en) 2005-05-06
DK1692516T3 (da) 2011-02-28
ATE490470T1 (de) 2010-12-15
EP2270511A2 (en) 2011-01-05
NZ546873A (en) 2010-09-30
JP5616880B2 (ja) 2014-10-29
JP4931593B2 (ja) 2012-05-16
JP2012093366A (ja) 2012-05-17
WO2005040816A1 (en) 2005-05-06
US20070202119A1 (en) 2007-08-30
BRPI0415533A (pt) 2006-12-26
EP2270511A3 (en) 2011-08-24
DE602004030369D1 (de) 2011-01-13
IL175141A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
PL1692516T3 (pl) Sposób terapii
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
MX2010004074A (es) Combinacion 059.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DK1599575T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af kardiovaskulære tilstande
PT1782825E (pt) Tratamento de doenças de armazenanto de glicogénio tipo ii
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
ATE546733T1 (de) Therapiestrategie zur behandlung von autoimmunkrankheiten und degenerativen erkrankungen
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
ATE409039T1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen
Bakhtar Amazing Topical Protocol and Novel Powder Dressing Combination Formula in Treatment of Diabetic Foot Wounds
MX2025007516A (es) Compuesto de naftilamida y metodo de preparacion del mismo y uso del mismo
RU2008142658A (ru) Способ лечения инфекционных поражений нервной системы
ATE339209T1 (de) Kombinationstherapie mit gemzitabin und zd6126
EA201600626A1 (ru) Способ повышения локального иммунитета при заболевании органов полости рта
RU98105539A (ru) Способ лечения псориаза
RU2002113511A (ru) Способ лечения одонтогенной аденофлегмоны
UA108637U (uk) СПОСІБ СТИМУЛЯЦІЇ РЕГЕНЕРАЦІЇ КІСТКОВОЇ ТКАНИНИ АКВАХЕЛАТАМИ Ag, Cu, Zn, Mg, Ca
CN1748652A (zh) 用“穴位割治法”根治颈淋巴腺结核
RU2002109170A (ru) Способ лечения больных хроническими цереброваскулярными заболеваниями